Presentation is loading. Please wait.

Presentation is loading. Please wait.

CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.

Published byCsilla Gulyásné Modified over 6 years ago

Similar presentations

Presentation on theme: "CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel."— Presentation transcript:

1 CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel 75 mg for 3 months (n = 84) vs. aspirin 80 mg plus placebo for 3 months (n = 87). Results (p = 0.035) Mean number of monthly migraine days per patient within 3 the months following ASD closure: 0.4 in the aspirin plus clopidogrel group vs. 1.4 in the aspirin plus placebo group (p = 0.035) New-onset migraine attacks: 9.5% in the aspirin plus clopidogrel group vs. 21.8% in the aspirin plus placebo group (p = 0.031) 1.4 0.4 Conclusions Among individuals undergoing percutaneous closure of an ASD, aspirin plus clopidogrel was effective at preventing new-onset migraine headache compared with aspirin alone This study confirms the occurrence of new-onset migraine headaches following ASD closure Aspirin plus clopidogrel Aspirin plus placebo Rodés-Cabau J, et al. JAMA 2015;314:

Download ppt "CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel."

Similar presentations

Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.

Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.

A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:842-857.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
(p for noninferiority = 0.01)

(p for noninferiority = 0.01)
IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.
Study Trial design No. of patients Randomisation Outcomes assessed

Study Trial design No. of patients Randomisation Outcomes assessed
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
(CMR vs. guidelines, p < 0.001)

(CMR vs. guidelines, p < 0.001)
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
(p < for group 1 or 2 vs. group 3)

(p < for group 1 or 2 vs. group 3)
IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for 40-80 days.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Similar presentations

Ads by Google